Synplogen, Ginkgo Bioworks Announce Plans To Accelerate Global DNA Manufacturing And Gene Therapy Platform Services In Japan
Portfolio Pulse from Benzinga Newsdesk
Synplogen and Ginkgo Bioworks have announced a collaboration to expedite DNA manufacturing and gene therapy services in Japan. Synplogen will facilitate the introduction of Ginkgo's services to the Japanese biotech and pharmaceutical sectors.
December 06, 2023 | 10:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ginkgo Bioworks, trading under the ticker DNA, is set to expand its gene therapy services in Japan through a partnership with Synplogen, potentially increasing its market presence and revenue streams in Asia.
The partnership with Synplogen is likely to open new opportunities for Ginkgo Bioworks in the Japanese market, which could lead to increased demand for their services. This expansion into a new geographical area is typically viewed positively by investors, suggesting a potential short-term uptick in the stock price.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80